

# Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

https://marketpublishers.com/r/T0FEB81A56FEN.html

Date: April 2018

Pages: 168

Price: US\$ 1,375.00 (Single User License)

ID: T0FEB81A56FEN

# **Abstracts**

### Report Scope:

This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.

The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.

The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.

#### Report Includes:

28 data tables and 9 additional tables



A comprehensive analysis of the ophthalmic device market by reviewing recent advances in diagnostic, surgical, and implantation devices that can be used to treat prevalent eye conditions.

Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022.

Breakdowns of the market by device, application, and region.

Analysis of the recent advances in ophthalmic medical devices and their potential impact on the medical device industry.

Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities.

Company profiles of major players in the market, including AbbVie Inc., Bristol-Myers Squibb, Clovis Oncology, Inc., Eli Lilly and Company and Pfizer Inc.



# **Contents**

#### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports

#### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

Market Context for Ovarian Cancer Therapies and Diagnostics

#### **CHAPTER 3 OVERVIEW AND BIOLOGY**

Overview

**Biology** 

Metastasis

Risk Factors

Family History

**Genetic Mutation** 

Lynch Syndrome

Peutz-Jeghers Syndrome

Age

**Previous Conditions** 

Prevention

Birth Control

**Childbearing Status** 

Removal of the Ovaries and Fallopian Tubes

Hysterectomy/Tubal Ligation

**Symptoms** 

Gastrointestinal

Abdominal

Whole Body

Diagnosis

Overview



**Current Screening Practices** 

Stages of Ovarian Cancer

Stage I

Stage II

Stage III

Stage IV

### **CHAPTER 4 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND**

Market Definition and Overview

**Market Drivers** 

Increase in Healthcare Expenditures

Continued Emphasis on R&D activities in Cancer and Treatment Technologies

Promised Potential of Alternative Therapies

Greater Understanding of the Genetic Base of Individual Cancers

Increasing incidences of Ovarian Cancer Worldwide

Greater Use of Combination Therapies for Treatment

Increasing Cancer Prevalence Rates and Aging Population

Rising Awareness Among People with Cancer and Its Treatment

**Market Restraints** 

Lack of Accurate Diagnosis of Ovarian Cancer

The Launch of Generic Drugs

Market Opportunities

Rising Female Population in the Asia-Pacific Region

Aging Demographics in Japan

Technological Advancements in the Drug Sector

Emergence of New Therapies for Disease Control

#### **CHAPTER 5 MARKET BREAKDOWN BY DIAGNOSIS**

Overview

Background

Diagnostic Tests

Pelvic Exam

**Laboratory Tests** 

Recurrent Ovarian Epithelial Cancer

**Market Forecast** 

**New Developments** 



#### **CHAPTER 6 OVARIAN CANCER TREATMENT**

**Treatment Strategies for Ovarian Cancer** 

**Current Treatment Practices** 

Surgery

Chemotherapy

Intraperitoneal Chemotherapy

IV Chemotherapy

**Targeted Therapy** 

**Immunotherapy** 

**Radiation Therapy** 

Palliative/Supportive Care

Recurrent Ovarian Cancer

Metastatic Ovarian Cancer

Sensitive Cancer Treatment

Resistant Cancer Treatment

Recurrent Ovarian Epithelial Cancer

Secondary Chemotherapy Drugs

Surveillance After Treatment

Novel Strategies for Prevention of Multidrug Resistance (MDR) in Cancer

#### **CHAPTER 7 MARKET BREAKDOWN BY CANCER TYPE**

**Epithelial Ovarian Tumors** 

Germ Cell Tumors

Stromal Tumors

**Primary Peritoneal Cancer** 

Stages of Ovarian Cancer

Stage

Stage

Stage

Stage

**Prognosis** 

## **CHAPTER 8 MARKET BREAKDOWN BY REGION**

Introduction

North America



#### U.S.

Canada

Europe

Acquisitions and Collaborations

Germany

## U.K.

France

Italy

Spain

Rest of Europe

Asia-Pacific

India

China

Japan

Middle East & Africa

Drivers

Restraints

Latin America

Mexico

**Drivers** 

Restraints

## **CHAPTER 9 PIPELINE ANALYSIS**

**Current Scenario** 

**New Product Developments** 

**VEGF** Inhibitor

PARP Inhibitors

Promising Pipeline Molecules/Drugs in Development

Atezolizumab

Avelumab

Lurbinectedin

Veliparib

**Trametinib** 

Fosbretabulin

Mirvetuximab Soravtansine



## Most Promising Drug

#### **ONX-0801**

Recent Developments in the Ovarian Cancer Treatment
Gene Therapy Inhibited Chemoresistant Tumor
Synthetic Gene Circuit Development
Novel Combination Therapy
Birinapant
CancerSEEK

#### **CHAPTER 10 PATENT ANALYSIS**

Overview

Patent Expiration

#### CHAPTER 11 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS

Overview

Major Players and Market Share
Mergers and Acquisitions
AbbVie and Stemcentrx
Hikma Pharmaceuticals and EIMC United Pharmaceuticals
Roche and Ignyta

# **CHAPTER 12 COMPANY PROFILES**

#### ABBVIE INC.

**Business Overview** 

**Products and Services** 

**Imbruvica** 

Venclexta

Pipeline analysis

Acquisitions

**Financials** 

#### **ASTRA ZENECA**



**Business Overview** 

**Products and Services** 

**Tagrisso** 

Lynparza

Faslodex (Fulvestrant)

Zoladex

**Ovarian Cancer Products** 

Developments and Strategies

Financials

#### **BRISTOL-MYERS SQUIBB**

Business Overview
Products and Services
Developments and Strategies
Financials

#### **CELGENE CORP.**

Business Overview
Products and Services
Financials

#### **CLOVIS ONCOLOGY**

Business Overview
Products and Services

#### **ELI LILLY AND COMPANY**

Business Overview
Products and Services
Gemzar
Developments and Strategies
Financials

## **GLAXOSMITHKLINE PLC**

#### **Business Overview**



Developments and Strategies Acquisition Financials

#### HIKMA PHARMACEUTICALS PLC

Business Overview
Products and Services
Developments and Strategies
Acquisitions
Financials

## JANSSEN PHARMACEUTICALS, INC.

Business Overview Financials

# MERCK & CO., INC.

Business Overview Financials

#### **MYRIAD GENETICS INC.**

Business Overview Products and Services Financials

#### **NOVARTIS AG**

Business Overview
Products and Services
Financials

#### PFIZER INC.

Company Overview Financials



## QUEST DIAGNOSTICS INC.

Business Overview Products and Services Financials

## **ROCHE HOLDING AG**

Business Overview
Products and Services
Acquisitions
Financials

# TESARO, INC.

Business Overview
Products and Services
Immuno-Oncology Platform



# **List Of Tables**

#### LIST OF TABLES

Summary Table A: Global Ovarian Cancer Therapeutic Market, by Cancer Type,

Through 2022

Summary Table B: Global Ovarian Cancer Therapeutic Market, by Region, Through 2022

Table 1: Imaging Tests and Functionality

Table 2: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for

Cancer, by Category, Through 2022

Table 3: Global Ovarian Cancer Therapeutics Market, by Cancer Type, Through 2022

Table 4: Stage 1 and Substages of Ovarian Cancer

Table 5: Stage 2 and Substages of Ovarian Cancer

Table 6: Stage 3 and Substages of Ovarian Cancer

Table 7: Stage 4 and Substages of Ovarian Cancer

Table 8: Global Ovarian Cancer Therapeutics Market, by Region, Through 2022

Table 9: North America Ovarian Cancer Therapeutics Market, Through 2022

Table 10: Europe Ovarian Cancer Therapeutics Market, Through 2022

Table 11: Asia-Pacific Ovarian Cancer Therapeutics Market, Through 2022

Table 12: Middle East and Africa Ovarian Cancer Therapeutics Market, Through 2022

Table 13: Latin America Ovarian Cancer Therapeutics Market, Through 2022

Table 14: PARP Inhibitors

Table 15: Pipeline Drugs Summary, by Phase

Table 16: Global Sales at Risk from Patent Expiration, 2016-2022

Table 17: Drugs Scheduled to Lose Patent Protection, 2018

Table 18: Drugs Scheduled to Lose Patent Protection, 2019

Table 19: Oncology Segment Revenue of Major Players, 2016

Table 20: AbbVie Inc.'s Revenue, 2015-2016

Table 21: AstraZeneca's Revenue, 2015-2016

Table 22: Lynparza's Revenue, 2015-2016

Table 23: Bristol-Myers Squibb's Revenue, 2015-2016

Table 24: Celgene Corp.'s Revenue, 2015-2016

Table 25: Eli Lilly and Company's Revenue, 2015-2016

Table 26: GlaxoSmithKline's Revenue, 2015-2016

Table 27: Hikma Pharmaceutical's Revenue, 2015-2016

Table 28: J&J's Revenue, 2015-2016

Table 29: Merck & Co., Inc.'s Net Revenue, 2014-2016

Table 30: Myriad Genetics, Inc.'s Revenue, 2015-2016



Table 31: Novartis AG's Revenue, 2015-2016

Table 32: Pfizer, Inc.'s Net Revenue, 2014-2016

Table 33: Quest Diagnostics, Inc.'s Revenue, 2015-2016

Table 34: Roche Holding's Revenue, 2015-2016

Table 35: Avastin's Drug Revenue, 2015-2016



# **List Of Figures**

#### LIST OF FIGURES

Summary Figure A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, 2016-2022

Summary Figure B: Global Ovarian Cancer Therapeutic Market, by Region, 2016-2022

Figure 1: Woman's Reproductive System

Figure 2: Ovarian Cancer Symptoms

Figure 3: Pelvic Examination

Figure 4: Transvaginal Ultrasound (TVUS)

Figure 5: Pelvic Examination

Figure 6: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, 2016-2022

Figure 7: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Ovarian Cancer, 2016-2022

Figure 8: Epithelial Cancer Therapy Market, 2016-2022

Figure 9: Germ Cell Cancer Therapy Market, 2016-2022

Figure 10: Stromal Cancer Therapy Market, 2016-2022

Figure 11: Primary Peritoneal Cancer Therapy Market, 2016-2022

Figure 12: Stage 1 and Substages of Ovarian Cancer

Figure 13: Stage 2 and Substages of Ovarian Cancer

Figure 14: Stage 3 and Substages of Ovarian Cancer

Figure 15: Stage 4 and Substages of Ovarian Cancer

Figure 16: U.S. Ovarian Cancer Therapeutics Market, 2016-2022

Figure 17: Canada Ovarian Cancer Therapy Market, 2016-2022

Figure 18: Germany Ovarian Cancer Therapy Market, 2016-2022

Figure 19: U.K. Ovarian Cancer Therapy Market, 2016-2022

Figure 20: France Ovarian Cancer Therapy Market, 2016-2022

Figure 21: Italy Ovarian Cancer Therapy Market, 2016-2022

Figure 22: Spain Ovarian Cancer Therapy Market, 2016-2022

Figure 23: RoE Ovarian Cancer Therapy Market, 2016-2022

Figure 24: India Ovarian Cancer Therapy Market, 2016-2022

Figure 25: China Ovarian Cancer Therapy Market, 2016-2022

Figure 26: Japan Ovarian Cancer Therapy Market, 2016-2022

Figure 27: Middle East and Africa Ovarian Cancer Therapy Market, 2016-2022

Figure 28: Mexico Ovarian Cancer Therapy Market, 2016-2022

Figure 29: Lurbinectedin Chemical Structure

Figure 30: Velaparib Chemical Structure



- Figure 31: Trametinib (Mekinist) Chemical Structure
- Figure 32: Fosbretabulin Chemical Structure
- Figure 33: Mirvetuximab Soravtansine Chemical Structure
- Figure 34: ONX-0801 Chemical Structure
- Figure 35: CancerSEEK Test
- Figure 36: Global Sales at Risk from Patent Expiration, 2016-2022
- Figure 37: Global Market Share of Major Players in OC Therapy Industry, 2016
- Figure 38: Merck & Co., Inc.'s Revenue Share, by Business Segment, 2016
- Figure 39: Merck & Co., Inc. Revenue Share, by Region, 2016
- Figure 40: Pfizer, Inc.'s Revenue Share, by Region, 2016
- Figure 41: Pfizer, Inc.'s Revenue Share, by Business Segment, 2016



#### I would like to order

Product name: Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

Product link: <a href="https://marketpublishers.com/r/T0FEB81A56FEN.html">https://marketpublishers.com/r/T0FEB81A56FEN.html</a>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/T0FEB81A56FEN.html">https://marketpublishers.com/r/T0FEB81A56FEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970